Gene sequencing test maker Illumina Inc. says its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately. The announcement was made Sunday. Charles Dadsw…
NEW YORK — Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.
Charles Dadswell, senior vice president and general counsel, has been named interim CEO, while the board conducts a search for a new CEO. Illumina said deSouza, who has been with the company since 2013 and was named CEO three years later, will stay on in an advisory capacity until July 31. “Illumina’s technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry,” Illumina’s board chair, Stephen P. MacMillan, said in a statement. “We are confident Illumina can continue to execute on its goals, while we conduct and complete a CEO search process.”The resignation comes as Illumina has been locked in a monthslong heated battle with activist investor Carl Icahn, over its $7.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Illumina CEO resigns following push by activist investor Carl Icahn to remove himResignation follows shareholder discontent around Illumina's acquisition of cancer diagnostic startup Grail
Read more »
Illumina CEO Francis DeSouza resigns after battle with IcahnIllumina Chief Executive Officer Francis DeSouza stepped down on Sunday, the gene-sequencing machine maker said in a statement, ending a battle with activist investor Carl Icahn in which the company's chairman left the company earlier this year.
Read more »
Illumina announces CEO transition plan as Francis deSouza resignsIllumina announced its board of directors has accepted the resignation of CEO Francis deSouza Sunday.
Read more »
Thanks to this North Texas company, It's payday for student athletes - CEO SpotlightBrent Chapman, CEO of myNILpay, Inc. joins David Johnson on this episode of CEO Spotlight.
Read more »
Rocky history of Illumina's Grail dealGene-sequencing machine maker Illumina Inc has filed an appeal against an order from the U.S. Federal Trade Commission (FTC) that demands it divest cancer diagnostic test maker Grail Inc due to competition concerns.
Read more »